Videos

Genprex Updates on Positive Pre-Clinical Results for its Immunotherapy Clinical Trial

Genprex, Inc. (NASDAQ:GNPX) Chairman and Chief Executive Officer, Rodney Varner, updates Proactive Investors on the latest developments with the Texas-based company's non-small cell lung cancer drug, including positive study results done in humanized mice.

Learn More

Genprex Retains Pharma Branding Agency to Select a Name for its Lead Drug

Genprex, Inc. (NASDAQ:GNPX) Chairman and CEO, Rodney Varner, tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate by retaining pharmaceutical branding agency, Addison Whitney, for the development of its non-proprietary and brand drug name.

Learn More

Genprex Reports Positive Pre-clinical Data on its Drug to Treat Lung Cancer

Genprex Inc (NASDAQ: GNPX) CEO Rodney Varner tells Proactive Investors that its collaborators from the University of Texas MD Anderson Cancer Center presented positive preclinical data linked to the company’s Oncoprex immunogene therapy for the treatment of lung cancer at the American Association of Cancer Research meeting.

Learn More

NobleCon 2019 / ChannelCheck

President and Chief Operating Officer, Julien Pham, MD, MPH, delivers a presentation about the company’s unique, leading-edge gene therapies and participated in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV.

Learn More

Biotech Showcase™ 2019 Lipid Nanoparticle-Encased TUSC2 Gene Underpins Phase II NSCLC asset

Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex™ which, in combination with erlotinib, is in Phase II testing against NSCLC.

Learn More

Genprex Strengthens its Team with New VP of Clinical Operations

Genprex Inc (NASDAQ:GNPX) COO Julien Pham tells Proactive Investors the clinical-stage gene therapy company has appointed Jan Stevens as its vice president of clinical operations. According to Pham, Stevens will support clinical development programs for the company’s immunogene therapy Oncoprex, which is being evaluated in...

Learn More

Genprex Reaches Deal with Aldevron for More Plasmid DNA for Expanding Clinical Program

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado at the MicroCap Conference in New York. The clinical-stage gene therapy company has reached a deal with Aldevron, a contract manufacturer, to receive a supply of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in its clinical...

Learn More

Genprex CEO Updates Investors on $10mln Capital Raise Progress of Oncoprex

Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado on the Austin, Texas-based biopharma's operations in the last few months, notably raising $10mln to be used toward continuing the company's clinical trial of Oncoprex,. Enrollment in Phase 1 and 2 studies for the cancer fighting drug has resumed...

Learn More

Genprex Making Strides to Take Cancer-Fighting Drug Oncoprex to FDA approval

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company's non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about...

Learn More

Genprex Developing the First Immunogene Therapy for the Treatment of Cancer

Julien Pham, MD, MPH and COO of Genprex, Inc. details our lead product candidate, Oncoprex™ (currently in development and not FDA approved). It uses a revolutionary approach to cancer treatment that combines the features of Gene Therapy, Immunotherapy, and Nanotechnology to harness the body’s own mechanisms to fight cancer.

Learn More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link